Table 3. Open in new tab Multivariable...

No n = 1079; yes n = 1374
Age (continuous variable)	0.98	0.98–0.99	<.001*	0.99	0.98–0.99	<.001*
<65 years	1.76	1.51–2.06	<.001*
Male	1.14	1.04–1.25	.004*	1.16	1.01–1.34	.03*
Hispanic	1.29	0.99–1.66	.05*
Non-Hispanic White	0.76	0.59–0.98	.03*	0.71	0.52–0.97	.03*
Black	1.37	1.18–1.59	<.001*	1.23	0.89–1.71	.21
Rural	1.04	0.93–1.16	.48
On immunosuppressive therapy	1.10	0.99–1.23	.07
Underserved	1.35	1.17–1.56	<.001*	1.10	0.68–1.36	.82
Both pneumococcal vaccines for those younger than age 65 years and immunosuppressed
No n = 578; yes n = 949
Age (continuous variable)	0.98	0.98–0.99	<.001*	0.99	0.98–0.99	<.001*
Male	1.02	0.89–1.15	.82
Hispanic	1.86	1.43–2.43	<.001*	1.68	1.27–2.22	<.001*
Non-Hispanic White	0.54	0.41–0.70	<.001*
Black	0.89	0.67–1.20	.46
Rural	1.18	1.02–1.37	.03*	1.24	1.07–1.45	.004*
Underserved	0.97	0.76–1.23	.77
Hepatitis B vaccine series
No, N = 1073; Yes, N = 1380
Age (continuous variable)	1.02	1.02–1.02	<.001*	1.02	1.02–1.02	<.001*
<65 years	0.66	0.61–0.73	<.001*
Male	1.00	0.92–1.10	.98
Hispanic	1.08	0.81–1.48	.54
Non-Hispanic White	1.19	1.00–1.40	.05*	0.76	0.61–0.93	.009*
Black	0.60	0.45–0.80	<.001*	0.50	0.34–0.74	.001*
Rural	1.30	1.18–1.43	<.001*	1.18	1.02–1.35	.02*
On Immunosuppressive therapy	0.70	0.64–0.77	<.001*	0.79	0.71–0.89	<.001*
Underserved	0.79	0.66–0.94	.009*	0.95	0.79–1.14	.56
Zoster vaccine for those age ≥50 years
No, n = 746; yes, n = 268
Age (continuous variable)	0.99	0.99–1.00	.13
Male	0.94	0.88–1.02	.14
Hispanic	1.18	0.97–1.45	.11
Non-Hispanic White	0.83	0.68–1.02	.08
Black	1.32	1.24–1.42	<.001*
Rural	0.98	0.89–1.07	.62
On immunosuppressive therapy	1.09	1.00–1.19	.05*	1.07	0.95–1.20	.25
Underserved	1.21	1.08–1.35	.001*	1.09	0.93–1.27	.30

No n = 1079; yes n = 1374

Univariable

Multivariable

95% CI

Age (continuous variable)

0.98

0.98–0.99

<.001*

0.99

0.98–0.99

<.001*

<65 years

1.76

1.51–2.06

<.001*

Male

1.14

1.04–1.25

.004*

1.16

1.01–1.34

.03*

Hispanic

1.29

0.99–1.66

.05*

Non-Hispanic White

0.76

0.59–0.98

.03*

0.71

0.52–0.97

.03*

Black

1.37

1.18–1.59

<.001*

1.23

0.89–1.71

.21

Rural

1.04

0.93–1.16

.48

On immunosuppressive therapy

1.10

0.99–1.23

.07

Underserved

1.35

1.17–1.56

<.001*

1.10

0.68–1.36

.82

Both pneumococcal vaccines for those younger than age 65 years and immunosuppressed

No n = 578; yes n = 949

Age (continuous variable)

0.98

0.98–0.99

<.001*

0.99

0.98–0.99

<.001*

Male

1.02

0.89–1.15

.82

Hispanic

1.86

1.43–2.43

<.001*

1.68

1.27–2.22

<.001*

Non-Hispanic White

0.54

0.41–0.70

<.001*

Black

0.89

0.67–1.20

.46

Rural

1.18

1.02–1.37

.03*

1.24

1.07–1.45

.004*

Underserved

0.97

0.76–1.23

.77

Hepatitis B vaccine series

No, N = 1073; Yes, N = 1380

Age (continuous variable)

1.02

1.02–1.02

<.001*

1.02

1.02–1.02

<.001*

<65 years

0.66

0.61–0.73

<.001*

Male

1.00

0.92–1.10

.98

Hispanic

1.08

0.81–1.48

.54

Non-Hispanic White

1.19

1.00–1.40

.05*

0.76

0.61–0.93

.009*

Black

0.60

0.45–0.80

<.001*

0.50

0.34–0.74

.001*

Rural

1.30

1.18–1.43

<.001*

1.18

1.02–1.35

.02*

On Immunosuppressive therapy

0.70

0.64–0.77

<.001*

0.79

0.71–0.89

<.001*

Underserved

0.79

0.66–0.94

.009*

0.95

0.79–1.14

.56

Zoster vaccine for those age ≥50 years

No, n = 746; yes, n = 268

Age (continuous variable)

0.99

0.99–1.00

.13

Male

0.94

0.88–1.02

.14

Hispanic

1.18

0.97–1.45

.11

Non-Hispanic White

0.83

0.68–1.02

.08

Black

1.32

1.24–1.42

<.001*

Rural

0.98

0.89–1.07

.62

On immunosuppressive therapy

1.09

1.00–1.19

.05*

1.07

0.95–1.20

.25

Underserved

1.21

1.08–1.35

.001*

1.09

0.93–1.27

.30

No n = 1079; yes n = 1374
Age (continuous variable)	0.98	0.98–0.99	<.001*	0.99	0.98–0.99	<.001*
<65 years	1.76	1.51–2.06	<.001*
Male	1.14	1.04–1.25	.004*	1.16	1.01–1.34	.03*
Hispanic	1.29	0.99–1.66	.05*
Non-Hispanic White	0.76	0.59–0.98	.03*	0.71	0.52–0.97	.03*
Black	1.37	1.18–1.59	<.001*	1.23	0.89–1.71	.21
Rural	1.04	0.93–1.16	.48
On immunosuppressive therapy	1.10	0.99–1.23	.07
Underserved	1.35	1.17–1.56	<.001*	1.10	0.68–1.36	.82
Both pneumococcal vaccines for those younger than age 65 years and immunosuppressed
No n = 578; yes n = 949
Age (continuous variable)	0.98	0.98–0.99	<.001*	0.99	0.98–0.99	<.001*
Male	1.02	0.89–1.15	.82
Hispanic	1.86	1.43–2.43	<.001*	1.68	1.27–2.22	<.001*
Non-Hispanic White	0.54	0.41–0.70	<.001*
Black	0.89	0.67–1.20	.46
Rural	1.18	1.02–1.37	.03*	1.24	1.07–1.45	.004*
Underserved	0.97	0.76–1.23	.77
Hepatitis B vaccine series
No, N = 1073; Yes, N = 1380
Age (continuous variable)	1.02	1.02–1.02	<.001*	1.02	1.02–1.02	<.001*
<65 years	0.66	0.61–0.73	<.001*
Male	1.00	0.92–1.10	.98
Hispanic	1.08	0.81–1.48	.54
Non-Hispanic White	1.19	1.00–1.40	.05*	0.76	0.61–0.93	.009*
Black	0.60	0.45–0.80	<.001*	0.50	0.34–0.74	.001*
Rural	1.30	1.18–1.43	<.001*	1.18	1.02–1.35	.02*
On Immunosuppressive therapy	0.70	0.64–0.77	<.001*	0.79	0.71–0.89	<.001*
Underserved	0.79	0.66–0.94	.009*	0.95	0.79–1.14	.56
Zoster vaccine for those age ≥50 years
No, n = 746; yes, n = 268
Age (continuous variable)	0.99	0.99–1.00	.13
Male	0.94	0.88–1.02	.14
Hispanic	1.18	0.97–1.45	.11
Non-Hispanic White	0.83	0.68–1.02	.08
Black	1.32	1.24–1.42	<.001*
Rural	0.98	0.89–1.07	.62
On immunosuppressive therapy	1.09	1.00–1.19	.05*	1.07	0.95–1.20	.25
Underserved	1.21	1.08–1.35	.001*	1.09	0.93–1.27	.30

Table 3.

Open in new tab

Multivariable models for prevalence ratio not receiving the vaccine influenza in both seasons.

No n = 1079; yes n = 1374
	Univariable			Multivariable
	PR	95% CI	P	PR	95% CI	P
Age (continuous variable)	0.98	0.98–0.99	<.001*	0.99	0.98–0.99	<.001*
<65 years	1.76	1.51–2.06	<.001*
Male	1.14	1.04–1.25	.004*	1.16	1.01–1.34	.03*
Hispanic	1.29	0.99–1.66	.05*
Non-Hispanic White	0.76	0.59–0.98	.03*	0.71	0.52–0.97	.03*
Black	1.37	1.18–1.59	<.001*	1.23	0.89–1.71	.21
Rural	1.04	0.93–1.16	.48
On immunosuppressive therapy	1.10	0.99–1.23	.07
Underserved	1.35	1.17–1.56	<.001*	1.10	0.68–1.36	.82
Both pneumococcal vaccines for those younger than age 65 years and immunosuppressed
No n = 578; yes n = 949
Age (continuous variable)	0.98	0.98–0.99	<.001*	0.99	0.98–0.99	<.001*
Male	1.02	0.89–1.15	.82
Hispanic	1.86	1.43–2.43	<.001*	1.68	1.27–2.22	<.001*
Non-Hispanic White	0.54	0.41–0.70	<.001*
Black	0.89	0.67–1.20	.46
Rural	1.18	1.02–1.37	.03*	1.24	1.07–1.45	.004*
Underserved	0.97	0.76–1.23	.77
Hepatitis B vaccine series
No, N = 1073; Yes, N = 1380
Age (continuous variable)	1.02	1.02–1.02	<.001*	1.02	1.02–1.02	<.001*
<65 years	0.66	0.61–0.73	<.001*
Male	1.00	0.92–1.10	.98
Hispanic	1.08	0.81–1.48	.54
Non-Hispanic White	1.19	1.00–1.40	.05*	0.76	0.61–0.93	.009*
Black	0.60	0.45–0.80	<.001*	0.50	0.34–0.74	.001*
Rural	1.30	1.18–1.43	<.001*	1.18	1.02–1.35	.02*
On Immunosuppressive therapy	0.70	0.64–0.77	<.001*	0.79	0.71–0.89	<.001*
Underserved	0.79	0.66–0.94	.009*	0.95	0.79–1.14	.56
Zoster vaccine for those age ≥50 years
No, n = 746; yes, n = 268
Age (continuous variable)	0.99	0.99–1.00	.13
Male	0.94	0.88–1.02	.14
Hispanic	1.18	0.97–1.45	.11
Non-Hispanic White	0.83	0.68–1.02	.08
Black	1.32	1.24–1.42	<.001*
Rural	0.98	0.89–1.07	.62
On immunosuppressive therapy	1.09	1.00–1.19	.05*	1.07	0.95–1.20	.25
Underserved	1.21	1.08–1.35	.001*	1.09	0.93–1.27	.30

No n = 1079; yes n = 1374
	Univariable			Multivariable
	PR	95% CI	P	PR	95% CI	P
Age (continuous variable)	0.98	0.98–0.99	<.001*	0.99	0.98–0.99	<.001*
<65 years	1.76	1.51–2.06	<.001*
Male	1.14	1.04–1.25	.004*	1.16	1.01–1.34	.03*
Hispanic	1.29	0.99–1.66	.05*
Non-Hispanic White	0.76	0.59–0.98	.03*	0.71	0.52–0.97	.03*
Black	1.37	1.18–1.59	<.001*	1.23	0.89–1.71	.21
Rural	1.04	0.93–1.16	.48
On immunosuppressive therapy	1.10	0.99–1.23	.07
Underserved	1.35	1.17–1.56	<.001*	1.10	0.68–1.36	.82
Both pneumococcal vaccines for those younger than age 65 years and immunosuppressed
No n = 578; yes n = 949
Age (continuous variable)	0.98	0.98–0.99	<.001*	0.99	0.98–0.99	<.001*
Male	1.02	0.89–1.15	.82
Hispanic	1.86	1.43–2.43	<.001*	1.68	1.27–2.22	<.001*
Non-Hispanic White	0.54	0.41–0.70	<.001*
Black	0.89	0.67–1.20	.46
Rural	1.18	1.02–1.37	.03*	1.24	1.07–1.45	.004*
Underserved	0.97	0.76–1.23	.77
Hepatitis B vaccine series
No, N = 1073; Yes, N = 1380
Age (continuous variable)	1.02	1.02–1.02	<.001*	1.02	1.02–1.02	<.001*
<65 years	0.66	0.61–0.73	<.001*
Male	1.00	0.92–1.10	.98
Hispanic	1.08	0.81–1.48	.54
Non-Hispanic White	1.19	1.00–1.40	.05*	0.76	0.61–0.93	.009*
Black	0.60	0.45–0.80	<.001*	0.50	0.34–0.74	.001*
Rural	1.30	1.18–1.43	<.001*	1.18	1.02–1.35	.02*
On Immunosuppressive therapy	0.70	0.64–0.77	<.001*	0.79	0.71–0.89	<.001*
Underserved	0.79	0.66–0.94	.009*	0.95	0.79–1.14	.56
Zoster vaccine for those age ≥50 years
No, n = 746; yes, n = 268
Age (continuous variable)	0.99	0.99–1.00	.13
Male	0.94	0.88–1.02	.14
Hispanic	1.18	0.97–1.45	.11
Non-Hispanic White	0.83	0.68–1.02	.08
Black	1.32	1.24–1.42	<.001*
Rural	0.98	0.89–1.07	.62
On immunosuppressive therapy	1.09	1.00–1.19	.05*	1.07	0.95–1.20	.25
Underserved	1.21	1.08–1.35	.001*	1.09	0.93–1.27	.30

This Feature Is Available To Subscribers Only